Loading
Life sciences · Journal article
Biosensing and Biomedicine · October 27, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Chimeric antigen receptor T cell (CAR-T) therapy has transformed hematological cancer treatment, but its broader clinical application remains constrained by the exorbitant costs and complex procedures of ex vivo manufacturing. To overcome these limitations, in vivo CAR-T engineering strategies are emerging as compelling alternatives, enabling direct reprogramming of T cells within the patients. Recent studies indicate that in vivo CAR-T therapy is evolving from a delivery-centered concept into an integrated engineering framework that should coordinate cell-selective targeting, controllable CAR expression, T-cell fitness, and long-term safety. Looking forward, this field is likely to move beyond vector innovation alone toward multidimensional platform design, which is comprehensively discussed in this perspective.